However, an expert consensus statement from the European Society for Medical Oncology concluded that there is insufficient evidence to support a prognostic value of HER2 expression within HER2-negative BC, citing inconsistencies in the results and small sample sizes of most studies [9]. Here, ERBB2 is linked to breast cancer.